Ultra-deep sequencing analysis of resistance-associated variants during retreatment with simeprevir-based triple therapy after failure of telaprevir-based triple therapy in patients with genotype 1 hepatitis C virus infection.
Naoki MorishitaNaoki HiramatsuTsugiko OzeAyako UrabeYuki TahataRyoko YamadaTakayuki YakushijinAtsushi HosuiSadaharu IioAkira YamadaHideki HagiwaraEiji MitaYukinori YamadaToshifumi ItoMasami InadaKazuhiro KatayamaIwao YabuuchiYasuharu ImaiHayato HikitaRyotaro SakamoriYuichi YoshidaTomohide TatsumiNorio HayashiTetsuo TakeharaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2016)
In this study, ultra-deep sequencing analysis revealed that TVR and/or SMV-resistant variants may have no influence on the effect of SMV-based therapy after failure of TVR-based therapy. Patients who discontinued treatment owing to adverse effects of TVR-based therapy and relapsers to previous pegylated interferon/ribavirin therapy would be good candidates for retreatment with SMV-based therapy.